Nitric oxide synthase inhibition versus norepinephrine in ovine sepsis: effects on regional blood flow.
Hypotension is a serious problem in septic patients. We investigated regional perfusion in several organs during treatment of hyperdynamic sepsis in sheep. Sepsis was induced and maintained for the entire experiment with a continuous infusion of live Pseudomonas aeruginosa. Treatment with either norepinephrine or the nitric oxide synthase inhibitor L omega-mono-methyl-arginine (L-NMMA) was begun after 24 h of sepsis and continued for 24 h. The norepinephrine dosage was adjusted to achieve the same increase in mean arterial pressure as that obtained by a fixed dose of L-NMMA (7 mg/kg/h). Blood flows were analyzed by the microsphere technique. Both compounds restored blood pressure effectively, but only L-NMMA caused a significant increase in systemic vascular resistance, concomitant with a significant fall in cardiac output. Sepsis caused an increase in myocardial blood flow and a redistribution of blood flow away from the pancreas and the stomach. Renal blood flow was not significantly elevated. During treatment with either compound, renal blood flow remained unchanged, despite a fall in cardiac output in the L-NMMA group. Unchanged renal blood flow combined with the restoration of arterial blood pressure caused a significant increase in urine output. Both L-NMMA and norepinephrine caused a redistribution of blood flow to the colon. Pancreatic blood flow was further reduced by L-NMMA but the oxygen extraction improved simultaneously, so that oxygen availability in the pancreas might have been unchanged. Because ischemic pancreatitis in sepsis is likely to trigger multiorgan failure, further investigations in that area are desirable.
Booke
M
M
Department of Anesthesiology, University of Texas Medical Branch, Galveston 77555-0833, USA.
Hinder
F
F
McGuire
R
R
Traber
L D
LD
Traber
D L
DL
D000818:Animals; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D007668:Kidney / Q000098:blood supply*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors*; D009638:Norepinephrine / Q000008:administration & dosage*; D010179:Pancreas / Q000098:blood supply*; D011550:Pseudomonas aeruginosa; D012039:Regional Blood Flow / Q000187:drug effects; D018805:Sepsis / Q000188:drug therapy* / Q000503:physiopathology; D012756:Sheep; D014662:Vasoconstrictor Agents / Q000008:administration & dosage*; D019323:omega-N-Methylarginine / Q000008:administration & dosage*
D004791:Enzyme Inhibitors; D014662:Vasoconstrictor Agents; D019323:omega-N-Methylarginine; D019001:Nitric Oxide Synthase; D009638:Norepinephrine